GSK to make grant info public

Share this article:
GlaxoSmithKline will join Pfizer and Eli Lilly in reporting educational and charitable grants.

The company will provide quarterly reports on grants to hospitals, teaching institutions, managed care organizations, professional associations, patient advocacy groups and CME companies starting in February of next year.

"GSK sponsors a range of third-party independent educational programs to increase awareness and knowledge of health-related issues,” said GSK president, North American pharmaceuticals, Chris Viehbacher in a statement. “By publishing information about our grants, we transparently identify the support we offer for independent and quality education to improve the delivery of health care for patients.”

Lilly began reporting its grants publicly in May 2007, and Pfizer followed suit a year later. In March, AstraZeneca vowed to publish grant information biannually.

In April, responding to an inquiry by Sen. Charles Grassley (R-IA) demanding to know whether they would follow Lilly's lead, several companies, including Bristol-Myers Squibb, Medtronic and Boston Scientific, also agreed to begin making information on educational grants and payments to physicians public, while others, including Abbott, Amgen and Merck, told the senator they were working on it. Only one of the firms Grassley wrote – Schering-Plough – declined outright.  
Share this article:

Email Newsletters

More in News

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.